drugset / Trial / NCT01614041

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder

NCT01614041

Phase 4 Completed 274 enrolled Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of comparative high dose Tandospirone Citrate in the treatment of patients with generalized anxiety disorder.

Timeline

Start
2012-01-10
Primary completion
2018-09-11
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tandospirone Small molecule 30 mg Oral
Comparator Tandospirone Small molecule 60 mg Oral